Novartis Flu Vaccine Problems Highlight Lack Of European Co-ordination
This article was originally published in The Pink Sheet Daily
Executive Summary
Quality issues that have seen two Novartis influenza vaccines suspended in a number of European countries have highlighted the shortfalls of a co-ordinated European approach to such problems.
You may also be interested in...
Fluad Adjuvant Could Come Under Fire At Advisory Committee
CSL’s (formerly Novartis’) flu vaccine was shown to be non-inferior, but not superior, on immunogenicity endpoints compared to an unadjuvanted vaccine in individuals ages 65 years and older.
Fluad's Italian Problem Could Reduce Confidence In Vaccines Across Europe
The EMA has given Novartis’ flu vaccine Fluad the all-clear after serious safety concerns were raised in Italy, but the publicity around the drug could pressure an already burdened vaccines industry.
German Vaccine Reforms Offer Multiple Tenders; Firms Want Purchase Guarantees
Government argues that shortages can be avoided by contracting with multiple manufacturers, but industry says changes do not go far enough, and is asking for sales assurances.